Matthew Cunningham, MD
Ophthalmology · Orlando, FLNPI 1336303247
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $240,889 of the $400,401 with a category attached, or 60.2%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.4%. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $920.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$94K
- Apellis Pharmaceuticals, Inc.$83K
- Astellas Pharma US Inc$78K
- Regeneron Healthcare Solutions, Inc.$66K
- Alcon$29K
- Novartis$15K
- plus $36K from 18 others
Across 710 payments — averaging $3604.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$976K
- Genentech, Inc.$572K
- Regeneron$485K
- Ocular Therapeutix, Inc.$148K
- ANI Pharmaceuticals, Inc.$123K
- Novartis$112K
- plus $144K from 7 others
What the payments were for
- Consulting fees$103,90926%
- Speaking & faculty fees$240,88960%
- Travel & lodging$37,0879%
- Food & beverage$15,6244%
- Education$1000%
- Ownership interest$1,1300%
- Other$1,6630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 85 | $93,803 |
| Apellis Pharmaceuticals, Inc. | 51 | $82,817 |
| Astellas Pharma US Inc | 53 | $78,049 |
| Regeneron Healthcare Solutions, Inc. | 72 | $66,321 |
| Alcon | 43 | $28,684 |
| Novartis | 23 | $14,938 |
| Alimera Sciences, Inc. | 28 | $10,127 |
| AbbVie(2 entities) | 39 | $9,957 |
| Ocular Therapeutix, Inc. | 5 | $4,727 |
| Alcon Research LLC | 3 | $4,660 |
| US Retina LLC | 6 | $2,792 |
| ANI Pharmaceuticals, Inc. | 9 | $2,274 |
| Eyepoint US, Inc. | 5 | $380 |
| Regeneron | 2 | $174 |
| Mallinckrodt Hospital Products Inc. | 2 | $117 |
| Harrow Eye, LLC | 1 | $116 |
| Genentech, Inc. | 1 | $109 |
| Beaver-visitec International, Inc. | 1 | $107 |
| Dutch Ophthalmic, USA | 1 | $92 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Bausch & Lomb Americas Inc. | 1 | $32 |
| Neurotech Pharmaceuticals, Inc. | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$400,401 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 106 | $231,256 |
| SyfovrePegcetacoplan/Pf | 23 | $50,370 |
| LucentisRanibizumab | 12 | $23,400 |
| Prednisolone Acetate | 331 | $13,426 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $8,732 |
| Ketorolac Tromethamine | 161 | $3,971 |
| Travoprost | 18 | $3,371 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 188 | $2,119 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 168 | $1,874 |
| Difluprednate | 14 | $1,871 |
| Brimonidine Tartrate | 108 | $1,865 |
| Latanoprost | 136 | $1,639 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $1,572 |
| Atropine Sulfate | 27 | $849 |
| Dorzolamide Hcl | 32 | $552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $66,321 | $231,256106 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $82,817 | $50,37023 claims |
| Genentech, Inc.Lucentis | $109 | $23,40012 claims |
| AbbVieCombigan | $9,957 | $8,73221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Orlando
- Sarina AminOrlando$138K
- Samuel Houston IiiOrlando$132K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.